Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon May 04, 2022 12:31pm
162 Views
Post# 34655374

RE:RE:Sesen (Vicineum) was disqualified on that

RE:RE:Sesen (Vicineum) was disqualified on that

I believe that we will have to apply with an NDA rather than a BLA.  Much easier IMO as TLD-1433 is an Organometallic substance ( pretty much like a salt) which is dissolved in saline when ready to be administered.  Already have shown 3 years of shelf life stability.   BLA is for a biological substance and much harder to produce and show consistency.  Manufacturing is very often an issue.  Biologics are also not as stable and have a much shorter shelf life.  All IMHO 


DJDawg wrote:
Quick question. I know biologic agents have different production challenges and concerns with safety and contamination in the manufacturing process.

Can we confirm that TLD-1433 has a more straightforward, non BLA production process? If so that probably reduces some of the Vicineum issues above around production. I think it does but thought I would confirm. More chance to satisfy FDA requirements in the long run.

 

<< Previous
Bullboard Posts
Next >>